Loading patent…
AssigneesAlnylam Pharmaceuticals, Inc., Imperial College of Science, Technology and Medicine
InventorsAntonin De Fougerolles, Andrew Sprague, Jens Harborth, Maria Gabriela Belvisi, Mark Andrew Birrell, Elizabeth Louise Hardaker, Matthew Copeland Catley
Estimating the term…
The invention relates to a doable-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the IKK-B gene, comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the IKK-B gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases, caused by the expression or activation of the IKK-B gene using the pharmaceutical composition; and methods for inhibiting the expression of the IKK-B gene in a cell.
A double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a human IKK-B gene, wherein said dsRNA comprises a sense strand and an antisense strand and a duplex structure between 15 and 30 base pairs in length, the antisense strand comprising at least 17 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:24.
Dependencies are inferred from the claim text.